KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Cash: 2009-2024

Historic Change in Cash for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $906.6 million.

  • Jazz Pharmaceuticals' Change in Cash fell 84.21% to $136.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$892.1 million, marking a year-over-year decrease of 201.09%. This contributed to the annual value of $906.6 million for FY2024, which is 45.09% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Change in Cash stood at $906.6 million for FY2024, which was up 45.09% from $624.8 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Change in Cash high stood at $906.6 million for FY2024, and its period low was -$466.3 million during FY2021.
  • Moreover, its 3-year median value for Change in Cash was $624.8 million (2023), whereas its average is $607.1 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Change in Cash tumbled by 210.92% in 2021, and later spiked by 162.20% in 2022.
  • Jazz Pharmaceuticals' Change in Cash (Yearly) stood at $420.4 million in 2020, then tumbled by 210.92% to -$466.3 million in 2021, then skyrocketed by 162.20% to $290.0 million in 2022, then spiked by 115.43% to $624.8 million in 2023, then skyrocketed by 45.09% to $906.6 million in 2024.